Trials / Completed
CompletedNCT04898946
Serological Response to mRNA and Inactivated COVID-19 Vaccine in Health Care Workers in Hong Kong
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 480 (actual)
- Sponsor
- Hong Kong Sanatorium & Hospital · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Since the first local case of COVID-19 confirmed on 4 Feb 2020, Hong Kong has already experienced 4 waves of COVID-19 surge, with more than 9000 cases reported. A number of vaccines have been shown to be efficacious against symptomatic and severe infection by inducing neutralizing antibody (NAB) against spike protein of the SARS-CoV-2 virus. However, the duration of protection and longevity of antibody response is unknown. Health care workers (HCWs) who are planning to receive COVID-19 vaccine will be recruited. The level of antibody against spike protein by different quantitative assays will also be serially measured .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CoronaVac Vaccine | CoronaVac Vaccine |
| BIOLOGICAL | BNT162b2 Vaccine | Covid-19 BNT162b2 Vaccine |
Timeline
- Start date
- 2021-03-07
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
- First posted
- 2021-05-24
- Last updated
- 2024-02-28
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT04898946. Inclusion in this directory is not an endorsement.